Seeking Alpha3d
Sanofi: Diverse Drug Portfolio And Future Pipeline, 4% Dividend Yield Looks Attractive
Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...
GEN2d
AI Collaboration Between Sanofi and Healx Will Target Novel Rare Diseases Indications
Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare ...
Trust matters but we also need these 3 things to boost vaccine coverage
While the inquiry gets most things right, as vaccine experts, we argue the government response should be broadened in three ...
labiotech11d
From consumer health to pure biopharma: Inside Sanofi’s strategic shift
Delve into Sanofi's "play to win" strategy as investments are ramping up after their consumer health division's divestment.
Regeneron, Sanofi Get New FDA Review of Dupixent for CSU
The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...
Reuters26d
Sanofi in exclusive talks with CD&R over sale of $17 billion Opella
PARIS, Oct 21 (Reuters) - French drugmaker Sanofi (SASY.PA), opens new tab said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella to U ...
FierceBiotech10d
ASH: Sanofi's BTK inhibitor raises platelet levels in 23% of ITP patients in phase 3
Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should spark some buyer’s delight. | Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should ...